RCUS Institutional Ownership

Arcus Biosciences, Inc.

Latest close $28.80 as of Aug 4, 2026

Schedule 13G/13D reports beneficial ownership at an observation date. “Accumulation” or “reduction” is inferred from changes in reported shares when available; it is not a list of individual trades or exact execution prices. Form 13F rows are quarter-end holding context only and do not establish an exact entry date.

Free access includes current parsed ownership filings, reported share changes, and ownership-percentage changes. Filing-specific significance scoring, disclosure-speed analysis, confirmation/divergence signals, and signal alerts require Investor or Pro. The overall institutional consensus preview remains public. Compare plans.

Cross-institution intelligence

Institutional Research

Each institution is compared with its own prior filing, then the latest institution-level directions are compared for breadth.

Latest filing Jan 8, 2026

Public consensus preview Accumulation leaning 66/100 institutional research score

2 tracked institutions Latest filing Jan 8, 2026

1 accumulating across 1 comparable institution.

Accumulating1

Unchanged0

Reducing0

Exited0

The overall consensus is public. Detailed holder comparisons, breadth history, ownership charts, and filing-specific signal analysis remain part of Investor and Pro research.

Price context

52-week position is market context and does not change the institutional consensus score.

52-week low$6.50 52-week high$26.40

Latest close $28.80 100.0% through the range

Tracked institutions

Public holder names and filing freshness. Detailed institution-by-institution analysis is locked.

Latest observation Dec 31, 2025

BlackRock Jan 8, 2026 filed

State Street Oct 17, 2024 filed

BlackRock Legacy Jan 23, 2024 filed

Detailed institutional research

See what is driving the consensus.

Unlock holder-by-holder changes, ownership history, breadth by period, disclosure timing, and filing-specific signal analysis.

Create free account Compare Investor and Pro

A free account adds watchlists and reveals tracker research gauges. Investor or Pro unlocks the detailed research above.

Beneficial ownership filing history

Showing 3 of 6 parsed filing(s) · 3 older require more history access

Holder	Observed / filed	Reported change	Shares	Ownership	Observation	Filing	Latest
BlackRock CIK0002012383	Dec 31, 2025 observed Jan 8, 2026 filed · 8d Schedule 13G amendment	Reported accumulation	12.7M +3.0M	12.00% +1.40 pts	$23.83	$21.35	$28.80
BlackRock CIK0002012383	Sep 30, 2024 quarter end Nov 13, 2024 filed Form 13F quarter-end evidence	Earlier Form 13F quarter-end holding Quarter-end holding evidence; no ownership percentage or signal.	9.7M		$15.29		$28.80
BlackRock CIK0002012383	Sep 30, 2024 observed Nov 8, 2024 filed · 39d Schedule 13G amendment	Reported shares unchanged	9.7M 0	10.60% 0.00 pts	$15.29	$17.85	$28.80

Explore more institutional activity

Related research

Crawlable links to other securities with similar institutional consensus or recent multi-institution accumulation.

Similar research strength

SNX TD SYNNEX CORP 66/100 Accumulation leaning CBAN COLONY BANKCORP 66/100 Accumulation leaning NRIX Nurix Therapeutics, Inc. 66/100 Accumulation leaning VGNT VERSIGENT PLC 66/100 Accumulation leaning

Recent multi-institution accumulation

TVTX Travere Therapeutics, Inc. 2 accumulating Aug 6, 2026 PCVX VAXCYTE INC 2 accumulating Aug 6, 2026 VVX V2X INC 2 accumulating Aug 6, 2026 VSEC VSE CORP 3 accumulating Jul 31, 2026